Akari Therapeutics, Plc AKTX
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -29.49%
- 1 year
- -71.89%
- Market cap
- 18.63M
- Shares out
- 26.47M
- Forward P/E
- -0.29
- YTD return
- -29.49%
- 1-year return
- -71.89%
- Volume
- 63.28K
- Avg volume
- 62.63K
- Open
- 8.39
- Previous close
- 7.57
- Day's range
- 7.99 – 8.61
- 52-week range
- 3.02 – 33.60
- Beta
- 0.95
- Earnings date
- May 6, 2024
15m -0.21 (-2.44%)
Key statistics
- Enterprise value
- 35.14B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -7.51M
- Total cash
- 4.18M
- Total debt
- 1.00M
- Return on equity
- 0.00%
- Short % of float
- 0.23%
- 50-day average
- 1.78
- 200-day average
- 2.41
Next earnings
May 6, 2024
Expected May 6, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 6, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Oct 3, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| Jul 19, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Jan 6, 2023 | Sep 1, 2022 | 0.00 | — | — | — |
| Sep 27, 2022 | Jun 1, 2022 | 0.00 | -2.00 | — | — |
About Akari Therapeutics, Plc
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- akaritx.com
News
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket 
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering 
Akari Therapeutics Submits PCT/US2026/45955 To Expand Its IP Portfolio 
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers 
Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest Update 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Your note
Sign in to keep a note on AKTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DICICCO WENDY FRANCES | Chief Financial Officer | Stock Award(Grant) | Apr 30, 2024 | 158,474,000 |
| PATEL SAMIR RASHMIKANT | Director | Stock Award(Grant) | Jun 27, 2024 | 3,502,890,000 |
| PRUDO-CHLEBOSZ RAYMOND M.D. | Director | Stock Award(Grant) | Dec 1, 2024 | 4,916,600,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Omnia Family Wealth, LLC | 0.33% | 87,628 | 85.88K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.13% | 33,260 | 32.59K | Sep 29, 2024 |
| Cerity Partners LLC | 0.09% | 23,643 | 23.17K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.07% | 18,069 | 17.71K | Sep 29, 2024 |
| Cresset Asset Management, LLC | 0.07% | 18,408 | 18.04K | Sep 29, 2024 |
| Cornerstone Planning Group LLC | 0.00% | 5 | 4 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 1,512 | 1.48K | Oct 30, 2024 |